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Abstract
Background Despite the crucial role of thiamine in glucose and energy metabolism pathways, there has been no published study
examining the impact of thiamine on energy metabolism in humans.
Objective To assess the effects of thiamine supplementation on resting energy expenditure (REE) in individuals with
hyperglycemia.
Methods Twelve hyperglycemic patients completed this double-blind, randomized trial, where all participants received both
thiamine (300 mg/day) and matched placebo for 6 weeks in a cross-over manner. REE was assessed by indirect calorimetry.
Anthropometric measurements, fasting and 2-h plasma glucose, and glucose-induced thermogenesis were also assessed at the
beginning and on the completion of each six-week phase.
Results Participants consuming thiamine supplements experienced a significant decrease in the REE assessed at week six
compared to the baseline [mean (SE): 1478.93 (73.62) vs.1526.40 (73.46) kcal/d, p = 0.02], and the placebo arm (p = 0.002).
These results did not change significantly after adjusting for the participants’ body weight and physical activity as potential
confounders. Six-week intervention had no significant effect on the participants’ body weight or waist circumference, in either
supplement or placebo arms (all p values>0.05). However, correlation analysis highlighted significant positive relationships
between the changes in REE, and those in fasting (rs = 0.497, p = 0.019) and 2-h plasma glucose (rs = 0.498, p = 0.018) during the
six-week intervention period.
Conclusion Supplementation with high-dose thiamine may attenuate REE in patients with impaired glucose regulation. Our
findings suggest that the impact of thiamine on REE may in part be explained by improved glycemic control.
Trial registration Australian New Zealand Clinical Trials Registry ACTRN12611000051943. https://www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?ACTRN=12611000051943
Keywords Thiamine . Vitamin B1 . Diabetes mellitus . Hyperglycemia . Glucose intolerance . Blood glucose . Energy
expenditure . Energymetabolism . Bodyweight
Introduction
Diabetes has reached epidemic proportions, affecting around
half a billion people worldwide. Additionally, over 370
million adults in the world are estimated to have impaired
glucose tolerance, according to the 2019 data from the
International Diabetes Federation [1]. It is known that hyper-
glycemia, in either diabetic or pre-diabetic ranges, can induce
various biochemical disturbances at the cellular level, leading
to both vascular and tissue damages [2, 3].
Existing evidence reveals that individuals with hyperglyce-
mia may have a higher resting energy expenditure (REE) com-
pared to normal people [4]. This could be in part due to an
increased rate of hepatic gluconeogenesis, which is an ener-
getically expensive process [5, 6]. Reciprocally, improving
hyperglycemia has been proposed to induce a reduction in
the energy expenditure in this group of patients [7].
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Thiamine is a water soluble vitamin playing a crucial role
as a co-enzyme in the pathways involved in glucose homeo-
stasis and energy metabolism [8, 9]. Emerging evidence indi-
cates that thiamin may modify specific mechanisms involved
in hyperglycemic complications [10–12]. Accordingly, thia-
mine supplementation has been implicated to have an array of
benefits for people with hyperglycemia [13–15].
Supplementation with high-dose thiamine was reported to de-
crease fasting plasma glucose in drug-naïve patients with T2D
[13], and improve glucose tolerance in hyperglycemic indi-
viduals [16]. Considering the association of hyperglycemia
and energy metabolism mentioned above, the effects of thia-
mine on blood glucose could be hypothetically accompaneed
by the changes in the energy metabolism as well.
There is also evidence indicating that administration of
thiamine-deficient diets can reduce food intake and increase
resting energy expenditure in experimental animals [17].
Despite these preliminary findings, there has been, however,
no published study examining the impact of thiamine on en-
ergy metabolism in humans. Thus, the present study investi-
gated the effect of high-dose thiamine supplementation on
energy expenditure in patients with hyperglycemia.
Methods
This was a randomized, double-blind crossover design trial,
conducted from May 2009 to March 2011 at Curtin
University, Australia. This study was approved by the Curtin
University Human Research Ethics Committee, and all partic-
ipants provided written informed consent.
Subjects
Seventeen hyperglycemic patients, comprising 14 individuals
with pre-diabetic hyperglycemia and 3 new cases of T2DM,
with a BMI 19–40 kg/m2 and aged 18–75 years participated in
the study. Participants were diagnosed as pre-diabetic (fasting
plasma glucose in the range 110–125 mg/dl, and/or 2-h
plasma glucose in the range of 140–199 mg/dl) or diabetic
(fasting plasma glucose ≥126 mg/dl and/or 2-h plasma glu-
cose ≥200 mg/dl) based on the WHO/IDF cut-offs for diag-
nosis of diabetes mellitus and intermediate hyperglycemia
[18]. Individuals with known impaired renal or liver function;
major cardiac, neurologic or gastrointestinal disorders; and
known allergy or intolerance to thiamine as well as current
smokers and women who were pregnant or breast feeding
were excluded from this study. No subject was onmedications
affecting the study outcomes or thiamine metabolism.
Participants who were on dietary supplements containing thi-
amine, or those who consumedmore than 2 standard alcoholic
drinks per day were instructed not to take the supplement and
reduce the alcohol intake during the study period, starting
4 weeks before the first clinical assessment.
Study design and procedure
Hyperglycemic participants were randomly assigned to two
groups; to receive either 100 mg thiamine (as thiamine hydro-
chloride) three times a day (300mg/day) or a matched placebo
for 6 weeks. Clinical measurements were performed at base-
line, week 3 and week 6. After completing the first phase and a
14-week wash-out period, participants received alternative
capsules for another 6 weeks. The measurements were then
repeated on the other three separate visits, similar to the first
part (Fig. 1). All participants and investigators who were in-
volved in data collection and analyses were blinded to the
treatment allocation. The thiamine capsules contained thia-
mine hydrochloride and the inactive ingredients starch and
lactose (Betamin, Sanofi-Aventis Australia Pty Ltd.,
Australia). The capsules provided as placebo were matched
with the supplement and contained only the inactive ingredi-
ents included in the thiamine capsules (starch and lactose).
Participants were instructed to keep to their usual diet and
level of physical activity throughout the study. To monitor
participants’ dietary habits, they were instructed to record all
food and drinks consumed over three consecutive days, in-
cluding 2 week-days and one weekend day, before baseline
Fig. 1 Study design. *, Seventeen hyperglycemic participants
commenced this randomized, double-blind crossover trial. Of those, four
subjects dropped out after completing the first phase (two participants
from each group) because of the time involved or starting the medication
for treatment of hyperglycemia. Another participant was excluded later,
due to the lack of compliance during the study. Data of twelve hypergly-
cemic patients were included for final analysis, where all participants
received both thiamine and matched placebo for 6 weeks in a cross-
over manner
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and week six clinical visits. They were also asked to consume
an unrestricted carbohydrate diet of at least 150–200 g of
carbohydrate/day for the 3 days before the glucose load, and
a standard meal provided by the investigators on the evening
before each clinical visit. On these days, participants attended
the out-patient clinic, School of Public Health, Curtin
University in the morning, following a 10–12 h overnight fast.
Anthropometric measurements were taken with participants
dressed in a gown with empty bladder and no shoes. The
participants’ body weight and height were measured to the
nearest 0.1 kg and 0.5 cm, using a calibrated body composi-
tion monitor (Model BC 541, Tanita Corporation, China) and
a portable stadiometer, respectively. Waist circumference was
measured at mid-exhalation, midpoint between the lateral
lower rib margin and the ileac crest using a non-elastic tape.
Fasting blood samples were then collected via venipuncture
into serum and plasma tubes. All participants also underwent a
75-g oral glucose tolerance test at the baseline and completion
of each 6-week phase. The second blood sample was collected
2 h after ingestion of the glucose beverage. Aliquots of plas-
ma, serum and red blood cell (RBC) samples were frozen at
−80 °C until analysis.
Measurements of energy expenditure
The impact of thiamine supplementation on the energy expen-
diture was assessed by indirect open-circuit calorimetry (hood
system) using a Deltatrac II machine (Datex, Helsinki,
Finland).The performance of the Deltatrac II metabolic mon-
itor was checked by alcohol burn tests as per the manufac-
turer’s instructions. Four alcohol burning tests were carried
out intermittently during the study period. The mean (±SD)
RQ value for the last 15 min of each test was 0.66 (± 0.02)
with a CVof 3.03% and within the acceptable range for RQ of
0.64–0.69. REEwasmeasured in the participants following an
overnight fast and an initial 30 min mandatory rest in a
temperature-controlled room (22 ± 2 °C).The duration of mea-
surement was 30 min and the average oxygen consumption
rate (VO2) and carbon dioxide production rates (VCO2) over
the last 25 min was used to calculate REE (kcal/24 h) by the
abbreviated Weir equation [19]. During the clinical visits at
baseline and week six, postprandial energy expenditure was
also measured for a period of 20 min just before taking the
second blood sample at 120 min. Change in 2 h EE was then
defined as the absolute increase of energy expenditure after
the glucose load.
Biochemical measurements
RBC thiamine pyrophosphate (RBC-TPP) was determined by
high-performance liquid chromatography (HPLC) with fluo-
rescent detection (pre-column derivatisation) using the
Chromsystems reagent kit (Chromsystems Instruments and
Chemicals GmbH, Munich, Germany) validated for RBC
samples [14]. Plasma glucose concentrations were measured
by the hexokinase method, using the Abbott diagnostic kits
(Abbott Laboratories, IL, USA) with an inter- and intra-run
coefficient of variation of <4.3%.
Compliance evaluation
In this study, the participants’ compliances were assessed by
1) capsule count and 2) participant self-report. If there was any
discrepancy between the participants’ compliances assessed
though the two described ways, the lesser value was reported
as the participant’s minimum compliance.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
version 19 (IBM Corp. Released 2010. Armonk, NY: IBM
Corp USA). A paired samples t-test was used to compare
the metabolic characteristics of participants at the baseline in
placebo and supplement arms. The effects of treatment (thia-
mine supplement) on clinical variables (energy expenditure
and biochemical measurements) were assessed using a linear
mixed-model analysis, with treatment, week and interaction
between treatment and week (treatment*week) as fixed ef-
fects. The relationships between the change in REE and other
variables of interest were assessed using Spearman’s rank-
order correlation coefficients (rs). To test the robustness of
the findings, we also performed an intention to treat analysis,
in which imputation was done for the missing values. Namely,
where the missing data occurred within a phase of the study
(Fig. 1), we used a last observation carried forward method. If
they occurred before the baseline of the second phase, missing
data in different visits of the second phase were inputted by
the means of the variable in the participants who completed
the study in the same arm and clinical visit. All tests were two-
tailed, and a p < 0.05 was considered as statistically signifi-
cant. Based on previous study [20], and the formula using for
calculating the sample size in clinical research [21], a sample
size of 12 participants in a cross-over study provides sufficient
power (80%) to detect a 8% change in REE at a 5% signifi-
cance level.
Results
Of seventeen participants who were recruited initially, four
subjects dropped out after completing the first phase (two
participants from each group) because of the time involved
or starting the medication for treatment of hyperglycemia.
Another participant was excluded later, due to the lack of
compliance during the study. Twelve participants (5 men and
7 women) including ten cases of IGT and two new cases of
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T2DM, with a mean (SE) BMI of 28.8 (1.2) kg/m2 and age of
57.2 (3.7) years completed the study. All twelve participants
received both placebo and thiamine capsules in a cross-over
design, with a compliance rate of at least 88% for the provided
treatment. There was no significant difference between clini-
cal characteristics of participants at baseline before they
embarked on the placebo or supplement arms of the cross-
over design (Tables 1 and 2). No adverse effects were reported
following either placebo or treatment arms of the trial.
Supplementation with thiamine increased the participants’
RBC-TDP levels from 49.07 (3.2) μg/l at the baseline to 86.60
(3.2) μg/l at week six (p < 0.001), with no significant change
in RBC-TDP levels of participants in the placebo arm [52.33
(3.2) vs. 52.02 (3.2) μg/l; p = 0.92]. While participants con-
suming thiamine supplement experienced a significant de-
crease in the REE assessed at week six compared to the base-
line [mean (SE):1478.93 (73.62) vs.1526.40 (73.46) kcal/d,
p = 0.02], there was no significant change in the REE between
week 6 and week 0 for those who received placebo
[1487.44(73.61) vs. 1500.91(73.46) kcal/d, p = 0.51]
(Table 2). There was also a significant difference between
supplement and placebo arms for the changes in the REE
during the six-week intervention period (p = 0.002). The trend
and significance of these outcomes remained the same even
after adjusting for the participants’ weight and physical activ-
ity levels as potential confounders [within supplement arm
(week 6 vs. week 0): p = 0.01; within placebo arm (week 6
vs. week 0): p = 0.18; between arms: p = 0.003]. Furthermore,
similar results were observed following the analysis of the
intention-to-treat population in the supplement (week 6:
1463.71 vs. week 0: 1514.55 kcal/d, p = 0.038) and placebo
(week 6: 1515.35 vs. week 0:1519.54 kcal/d, p = 0.868) arms.
Six-week intervention had no significant effect on the partic-
ipants’ weight or waist circumference in either supplement or
placebo arms (Table 1). Similarly, no significant change was
found in the supplement or placebo arms for fasting and 2-h
respiratory quotient or glucose induced thermogenesis (all p-
values>0.05). Subsequent correlation analysis highlighted
significant positive relationships between the change in REE
with the changes in fasting (rs = 0.497, p = 0.019), and 2-h
plasma glucose (rs = 0.498, p = 0.018) during the six-week
intervention period (Fig. 2).
Discussion
In the present study, supplementation with high-dose thiamine
for 6 weeks resulted in a significant decrease in REE compared
to the baseline and placebo. As indicated before, to our knowl-
edge there has been no clinical trial evaluating the impact of
thiamine supplementation on energy metabolism in humans.
However, our findings are partially in line with an experimental
study indicating that administration of a thiamine - deficient
diet for 25 days increased REE (by approximately 10 folds)
in an animal model. Subsequent thiamine re-supplementation
then rapidly attenuated REE to the control level [17].
It was demonstrated that patients with type 2 diabetes or
impaired glucose tolerance may have higher rates of REE
compared to normoglycemic people [4, 20, 22–24]. There is
evidence suggesting that an increase in fasting hepatic gluco-
neogenesis as well as glycosuria resulting from hyperglyce-
mia may be behind the high REE observed in diabetic patients
[22, 25]. Up-regulation of energy expenditure by hyperglyce-
mia has been proposed to be partially mediated via AMP-
Table 1 Characteristics of participants in different visits by the study arms
Placebo arm Thiamin arm Between arms
p value
Week 0 Week 3 Week 6 Pa Pb Week 0 Week 3 Week 6 Pa Pb
Weight (kg) 83.13 (4.2) 83.55
(4.2)
83.49 (4.2) 0.37 0.88 83.50 (4.2) 83.35
(4.2)
83.30 (4.2) 0.62 0.90 0.22
WC (cm) 97.62 (2.9) 97.83
(2.9)
97.66 (2.9) 0.90 0.63 98.04 (2.9) 98.10
(2.9)
97.9 (2.9) 0.72 0.60 0.65
FPG (mg/dl) 105.7 (3.7) 105.7
(3.7)
109.9 (3.7) <0.01 <0.01 108.4 (3.7) 107.7
(3.7)
108.1 (3.7) 0.82 0.77 <0.01





RBC-TDP (μg/l) 52.33 (3.2) – 52.02 (3.2) 0.92 – 49.07 (3.2) – 86.60 (3.2) <0.001 – <0.001
Dietary thiamine
intake (mg/d)












Data are presented as mean (SE); a, linear mixed model analysis: compare difference between week 0 and week 6; b, Linear mixed model analysis:
compare difference between week 3 and week 6; compare between arm difference; FPG, fasting plasma glucose; 2-h PG, plasma glucose 2 h after
glucose load
J Diabetes Metab Disord
activated protein kinase (AMPK), which is a crucial energy-
sensing enzyme [26]. AMPK is activated when cells are ex-
posed to a variety of metabolic stresses including energy dep-
rivation or hypoglycemia [27, 28]. Upon activation, AMPK
inhibits ATP-consuming pathways such as gluconeogenesis,
and stimulates ATP-producing pathways including fatty acid
oxidation and glucose uptake by cells [26]. On the contrary,
AMPK activity/phosphorylation has been shown to decrease
in the presence of high glucose concentration [29] or an in-
crease in the cellular glycogen stores [30].
Emerging evidence indicates that thiamine may influence







































































































































































































































































































































































































































































































































































































































































































































































r  =0.497 p =0.019
R2 Linear = 0.201
a



















R2 Linear = 0.247
r  =0.498, p =0.018
b
Fig. 2 Scatterplot of the changes (week 6 – week 0) in fasting plasma
glucose (FPG) (a) and change in 2 h-plasma glucose (b) vs. resting energy
expenditure (REE)
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an experimental study by Tabidi et al. [31], incubation of
cardiac myocytes with 5 mM glucose resulted in an 82% de-
crease in AMPK activity. The addition of thiamine to the
incubation buffer could then attenuate the effect of glucose
on AMPK activity, and increase AMPK phosphorylation in
the myocytes. The exact mechanisms by which thiamine im-
proves AMPK activity under hyperglycemic condition are not
fully elucidated. However, considering the key role of thia-
mine as the precursor of the TDP (thiamine diphosphate) an
essential coenzyme for transketolase in the pentose phosphate
pathway, it was proposed to modify some intermediates of the
pentose phosphate pathway triggering the inactivation of
AMPK by glucose [12, 31].
As mentioned previously, individuals with hyperglycemia
are known to have a relatively higher resting energy expendi-
ture compared to healthy people [4], and existing evidence
confirms a reciprocal decrease in the basal metabolic rate fol-
lowing an improvement in the glycemic control [7]. Given the
positive effects of thiamine on hyperglycemia reported in both
diabetic [13, 32] and pre-diabetic patients [16], it seems that,
apart from modulating glucose effect on AMPK activity
discussed above, thiamine therapy may also primarily reduce
REE as a result of controlling blood glucose; this notion is
supported by the significant correlation between the six-week
change in REE and the changes in the fasting and 2-h plasma
glucose observed in the present study. In this context, it should
be also noted that this study included participants with hyper-
glycemia mostly at the pre-diabetic ranges, expecting to have
a REE higher than normal but not as high as those in individ-
uals with diabetes [20]. Accordingly, supplementation with
high-dose thiamine may hypothetically induce more signifi-
cant changes in REE of diabetic patients. Further research is
required to explore this assumption more definitely.
In the present study, decreases in the REE of participants in
the supplement arm were not associated with significant
changes in their body weight or waist circumference. An ex-
perimental study showed that the reduced REE resulted from
thiamine re-supplementation in thiamine deficient mice was
accompanied by stimulation of hypothalamic AMPK activity
and increased appetite and food intake, causing an overall
body weight gain [17]. However, the findings of human stud-
ies investigating the effect of thiamine on the body weight
have been controversial: in a clinical trial conducted by
Wilkinson et al. [33] thiamine supplementation (10 mg/d)
for 3 months resulted in a considerable decrease in the weight
of older participants with persistent subclinical thiamine defi-
ciency confirmed on two occasions, but not in those with just
an isolated low thiamine concentration. No exact explanation
was offered byWilkinson et al. for this finding. However, they
explained a likely improvement in the heart failure of partic-
ipants taking Furosemide and a subsequent weight loss
resulting from diuresis as a notable point. By contrast, Smidt
et al. [34] reported a significant increase in the body weight of
elderly participants with marginal thiamin deficiency taking
thiamine supplement (10 mg/d) for 6 weeks, which was ac-
companied by significant improvements in their appetite and
energy intake. In another study, dietary intake of thiamine
(mg/kcal) was significantly correlated with the body mass
index, on the basis of a gender difference (positive and nega-
tive correlations in men and women, respectively) [35]. The
inconsistency between our results for the body weight and the
findings of previous studies may be in part due to the fact that
those studies were mainly conducted on normoglycemic peo-
ple with subclinical/marginal thiamine deficiency. However,
all participants of our study were hyperglycemic and had a
normal thiamine status at the baseline. More comprehensive
studies investigating the association of thiamine with the body
weight in normal and hyperglycemic people / with or without
underlying thiamine deficiency would be worthwhile.
The strength of the present study is that it is the first
to examine the effect of thiamine on energy expenditure
in humans. However, this study has some limitation as
well. First of all, the sample size of the study is rela-
tively small, limiting us to evaluate the impact of thia-
mine on REE in men and women, or in the subgroups
of diabetics and pre-diabetics, separately. In the present
study, we were also unable to evaluate the participants’
body composition. Therefore, although the thiamine-
induced decrease in REE was not associated with a
significant change in body weight, it is not possible to
identify an impact on body composition.
In conclusion, this study provided evidence indicating
that high-dose thiamine supplementation may attenuate
REE in patients with hyperglycemia at an early stage.
We also found a positive correlation between the change
in REE and amendments in fasting and 2-h plasma glu-
cose, suggesting that the impact of thiamine supplemen-
tation on REE may partly result from improving hyper-
glycemia. Considering the lack of previous research on
this topic, further research with a larger sample size is
required to confirm these results and elucidate the pos-
sible mechanisms. Moreover, future clinical studies ex-
ploring the effect of thiamine on food intake, energy
metabolism and body composition in normal individuals
as well as patients with hyperglycemia, in either diabet-
ic or pre-diabetic ranges, may provide a novel insight
into the regulation of body weight and new preventive/
therapeutic strategies.
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